These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19195430)

  • 1. [Introduction. Tenofovir].
    Mallolas J
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():1. PubMed ID: 19195430
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.
    Francisci D; Falcinelli E; Belfiori B; Petito E; Fierro T; Baldelli F; Gresele P
    AIDS Patient Care STDS; 2011 Oct; 25(10):567-9. PubMed ID: 21851265
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
    Pulido F; Fiorante S
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():13-8. PubMed ID: 19195433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].
    Bernardino de la Serna JI; Mora Rillo M; Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():7-12. PubMed ID: 19195432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level.
    Wirden M; Marcelin AG; Tubiana R; Valantin MA; Ghosn J; Duvivier C; Dominguez S; Paris L; Agher R; Peytavin G; Katlama C; Calvez V
    J Acquir Immune Defic Syndr; 2004 Jul; 36(3):876-8. PubMed ID: 15213573
    [No Abstract]   [Full Text] [Related]  

  • 6. [Conclusions. Tenofovir].
    Mallolas J
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():62-4. PubMed ID: 19195439
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tenofovir: pharmacology and interactions].
    Azanza JR; García Quetglas E; Sádaba B; Gómez-Giu A
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():2-6. PubMed ID: 19195431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current role of tenofovir in clinical medicine].
    Ribera Pascuet E; Curran A
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():45-54. PubMed ID: 19338072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
    Kagan RM; Lee TS; Ross L; Lloyd RM; Lewinski MA; Potts SJ
    Antiviral Res; 2007 Sep; 75(3):210-8. PubMed ID: 17442410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tenofovir DF in rescue regimens].
    López Bernaldo de Quirós JC
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():25-30. PubMed ID: 19195435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
    Winston A; Mandalia S; Pillay D; Gazzard B; Pozniak A
    AIDS; 2002 Oct; 16(15):2087-9. PubMed ID: 12370512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens.
    van Leth F; Prins JM; Lange JM; Geerlings SE
    AIDS; 2005 Oct; 19(15):1722-3. PubMed ID: 16184059
    [No Abstract]   [Full Text] [Related]  

  • 13. [Tenofovir as a strategy to avoid or limit adverse effects].
    Portilla J
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():19-24. PubMed ID: 19195434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
    Fung HB; Stone EA; Piacenti FJ
    Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elvucitabine data released at CROI.
    AIDS Patient Care STDS; 2010 Mar; 24(3):198. PubMed ID: 20235383
    [No Abstract]   [Full Text] [Related]  

  • 16. Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.
    Mastroianni CM; d'Ettorre G; Vullo V
    Expert Opin Pharmacother; 2006 Nov; 7(16):2233-41. PubMed ID: 17059380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.
    Valer L; Martín-Carbonero L; de Mendoza C; Corral A; Soriano V
    AIDS; 2004 Oct; 18(15):2094-6. PubMed ID: 15577635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

  • 20. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results.
    Domingo P; Labarga P; Palacios R; Guerro MF; Terrón JA; Elías MJ; Santos J; Ruiz MI; Llibre JM;
    AIDS; 2004 Jul; 18(10):1475-8. PubMed ID: 15199328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.